Tradestie Institutional Equity Comparison Engine
SLN vs EVMN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EVMN Overall Edge
EVMN Captures Institutional Edge (2โ1 Pillars ยท 2โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while SLN counters with relative strength in Momentum & Technical. Fundamentally, SLN trades at N/M Forward P/E with -10475.6% operating margin (+197.2% YoY revenue) versus EVMN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SLN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SLN N/M vs EVMN N/M Fwd P/E
Growth & Margin Winner
EVMN
Op Margin -10475.6% vs 0.0% ยท YoY +197.2% vs +0.0%
Momentum & Technical Winner
SLN
1Y +186.1% vs -61.0% ยท 52W Pos 100% vs 8%
Options & Structure Winner
EVMN
UNCLASSIFIED (50th %ile IV) vs SURGE (53rd %ile IV)
SLN
NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.80
-0.15% 1D
Market Cap
$1.2B
1M Return
+128.11%
1Y Return
+186.13%
Forward P/E
N/M
Unified AI Score
46.9 / 100
HOLD
Tech 24.0
Fund 34.0
Flow 50.0
Mom 30.0
EVMN
US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap
$315.5M
1M Return
+37.33%
1Y Return
-61.03%
Forward P/E
N/M
Unified AI Score
30.0 / 100
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SLN +186.13%
EVMN -61.03%
Spread: +247.16 pp (SLN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SLN TTM Op. Margin: -10475.6%
EVMN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLN vs EVMN. Trailing 12-month operating profitability (SLN -10475.6% vs EVMN 0.0%) and valuation multiples (SLN N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SLN | EVMN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $315.5M | Larger Scale | SLN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +197.2% | +0.0% | Higher Growth | SLN |
| Operating Margin (TTM) Profitability | -10475.6% | 0.0% | Higher Margin | EVMN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -90.4% | -69.5% | Higher ROE | EVMN |
| 52-Week Range Position Momentum | 100% ($4โ$20) | 8% ($5โ$33) | Stronger Trend | SLN |
| Beta / 30D Volatility Risk Regime | 1.91ฮฒ ยท 4% Vol | 1.05ฮฒ ยท 118% Vol | Lower Realized Risk | SLN |
| Unified Institutional Score Composite Signal | 46.9 / 100 (HOLD) | 30.0 / 100 (SELL) | Higher Composite | SLN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SLN vs EVMN Buy Guide
SLN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
50th %ile
IV Regime
Balanced (25thโ60th %ile)
EVMN
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
53rd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SLN nor EVMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.